Control group:Regorafenib

2 trials

Sponsors

Zhongshan Hospital, Fudan University, Huashan Hospital Affiliated to Fudan University

Conditions

colorectal liver metastaseshepatocellular carcinoma

Phase 2

A single-center, prospective, randomized clinical trial of EGFR inhibitor plus lenvatinib versus regorafenib in lenvatinib-resistant EGFR-positive advanced HCC patients

Active, not recruitingChiCTR2200062854

Huashan Hospital Affiliated to Fudan Universityhepatocellular carcinoma

Start: 2022-08-25Updated: 2023-04-12

Unknown Phase

Efficacy and safety of drug-eluting microspheres combined with anti-angiogenic drugs in the treatment of colorectal liver metastases who have failed second-line chemotherapy in China

RecruitingChiCTR2100045317

Zhongshan Hospital, Fudan Universitycolorectal liver metastases

Start: 2021-07-01Updated: 2021-11-22